Details for Patent: 8,895,718

Summary for Patent: 8,895,718

Title:	RNA interference mediating small RNA molecules
Abstract:	Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a Drosophila in vitro system, we demonstrate that 19-23 nt short RNA fragments are the sequence-specific mediators of RNAi. The short interfering RNAs (siRNAs) are generated by an RNase III-like processing reaction from long dsRNA. Chemically synthesized siRNA duplexes with overhanging 3' ends mediate efficient target RNA cleavage in the lysate, and the cleavage site is located near the center of the region spanned by the guiding siRNA. Furthermore, we provide evidence that the direction of dsRNA processing determines whether sense or antisense target RNA can be cleaved by the produced siRNP complex.
Inventor(s):	Tuschl; Thomas (Brooklyn, NY), Elbashir; Sayda Mahgoub (Cambridge, MA), Lendeckel; Winfried (Hohengandern, DE)
Assignee:	Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V. (Munich, DE) Massachusetts Institute of Technology (Cambridge, MA) Whitehead Institute for Biomedical Research (Cambridge, MA) University of Massachusetts (Boston, MA)
Application Number:	12/897,374
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent 8,895,718

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 8,895,718

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1407044		132019000000031	Italy
Austria	373724
Austria	450621
Austria	542899
Australia	2001249622
Australia	2002235744
Australia	2007203385